Suppression of mammary gland tumorigenesis in diabetic rats

Cancer Detection and Prevention

Volumn 27, Issue 1, 2003, Pages 37-46

  Cocca, Claudia ^a   Gutiérrez, Alicia ^a   Núñez, Mariel ^a   Croci, Máximo ^b   Martín, Gabriela ^a   Cricco, Graciela ^a   Rivera, Elena ^a   Bergoc, Rosa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Institute of Immunooncology Dr Ernesto Crescenti   (Argentina)

Author keywords

Diabetes; IGF I; Insulin; Mammary tumors; Multistep carcinogenesis; Rats

Indexed keywords

ALKYLATING AGENT; CYCLINE; INSULIN; METHYLNITROSOUREA; SOMATOMEDIN C;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; ONCOGENE; PANCREAS; PATHOLOGY; PHYSIOLOGY; RAT; TIME;

ALKYLATING AGENTS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GENES, FOS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; PANCREAS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; TIME FACTORS;

EID: 0242585467     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00130-7     Document Type: Article

References (48)

1. Figueroa JA, Jackson JG, McGuire W, et al. Expression of insulin-like growth factor binding protein in human breast cancer correlates with estrogen receptor status. J Cell Biochem 1993;52:196-205.
2. Russo H, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998;3(1):49-81.
3. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effect of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Rev 2000;21(3):215-44.
4. Kamysheva EP, Abelevich IG, Andriukhina C, et al. Diabetes mellitus and cancer. Ross Med Zh 1992;2:8-11.
5. Levin E, Levin RW. Better evolution of breast cancer in type II diabetic patients under tamoxifen hypoglycemic sulfonylureas treatment. Abstracts V Int Congress Hormones & Cancer, Quebec, 1995.
6. Rhomberg W. Metastasirendes mammakarzinom und diabetes mellitus-eine prognostisch günstinge krankheitskombination. Dtsch Med Wschr 1975;100:2422-7.
7. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)antracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 1972;32:226-32.
8. Cohen ND, Hilf R. Influence of insulin on growth and metabolism of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors. Cancer Res 1979;34:3245-52.
9. Werner H, Le Roith D. New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci 2000;57(6):932-42.
10. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth. Cancer Res 1995;55:249-52.
11. Rasmussen AA, Cullen KF. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factor. Breast Cancer Res Treat 1998;47:219-33.
12. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 1994;32:85-95.
13. Lønning PE, Kalk K, Aakvaag A, et al. Influence of Tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992;52:4719-23.
14. Giustina A, Ruggeri G, Bodini C, et al. Int Sympos Biotechnol Growth Factors. In: Lefant C, Paoletti R, Albertini A, editors. Milan; 1992. p. 115-22.
15. Häring A, Kelleler M, Mosthaf L. Modulation of insulin signaling in non-insulin dependent diabetes: significance of altered receptor isoforms pattern and mechanisms of glucose-induced receptor modulation. Horm Res 1994;41:87-92.
16. Clauson PG, Brismar K, Hall K, et al. Insulin-like growth factor-I and insulin-like growth factor binding protein-I in representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 1998;54(4):353-60.
17. Gibson JM, Westwood M, Crosby SR, et al. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-I in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;80(4):1369-75.
18. Shinada M, Akdeniz A, Panagiotopoulus S, et al. Proteolisis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy. J Clin Endocrinol Metab 2000;85(3):1163-9.
19. Schuchard M, Landers JP, Sandhu NP, et al. Steroid hormone regulation of nuclear protooncogenes. Endocrinol Rev 1993;14:659-69.
20. Hyder SM, Stancel GM, Narvaz Z, et al. Identification of an estrogen response element in the 3′-planning region of the murine c-fos protooncogene. J Biol Chem 1992;267:18047-54.
21. Gee JM, Willsher PC, Kenny FS. Endocrine response and resistance in breast cancer: a role for the transcription factor fos. Int J Cancer 1998;84(1):54-61.
22. Dietrich RD. Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA): a novel endogenous marker for cell proliferation. Crit Rev Toxicol 1993;23(1):77-109.
23. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997;14:81629-40.
24. Rivera E, Melito G, Davio C, et al. Histopathology and influence of the estral cycle on NMU-induced tumors in rats. Cancer Lett 1994;86:223-8.
25. Guide for the Care and Use of Laboratory Animals, National Research Council, Washington (DC): National Academy Press; 1996.
26. Weir GC, Clare ET, Zmachinski CJ, et al. Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 1981;30:590-5.
27. Cocca C, Binda M, Martin G, et al. Diabetes and Cancer. Medicina 1995;55:492.
28. Cocca C, Martin G, Rivera E. An experimental model of diabetes and cancer in rats. Eur J Cancer 1998;34:889-94.
29. Russo J, Russo IH, Rogers MJ, et al. Tumors of the mammary gland. In: Turusov VS, Mohr U, editors. Pathology of tumors in laboratory animals. Tumors of the rats, vol. 1. Lyon (France): IARC Scientific Publications No. 99; 1990.
30. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000;5:187-200.
31. Gomori G. A rapid one-step trichromic stains. Am J Clin Path 1950;20:661-4.
32. Agresti A., Categorical data analysis. New York: Wiley; 1990.
33. Winer B, Brown D, Michels K. Statistical principles in experimental design. New York: McGraw-Hill; 1991.
34. Martin G, Melito G, Rivera E, et al. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors. Cancer Lett 1996;100:227-34.
35. Martin G, Rivera E, Davio C, et al. Receptors characterization of intraperitoneally N-nitroso-N-methylurea-induced mammary tumors in rats. Cancer Lett 1996;101:1-8.
36. Martin G, Davio C, Rivera E, et al. Hormone dependence of mammary tumors induced in rats by intraperitoneal NMU injection. Cancer Invest 1997;15(1):8-17.
37. Martin G, Cricco G, Davio C, et al. Epidermal growth factor in NMU-induced mammary tumors in rats. Breast Cancer Res Treat 1998;48:175-85.
38. Frystyk J, Grømbok H, Skjaek C, et al. Development changes in serum levels of free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit in rats. Endocrinology 1998;139:4286-92.
39. Kieinberg CL, Feldman W, Ruan W. IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neoplasia 2000;5(1):7-17.
40. Pollack M. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998;47:209-17.
41. Pollack M, Constantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-7.
42. Hankinson SE, Willet WC, Colditz CA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351(9113):1393-6.
43. Peirat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 1993;29A:492-7.
44. Basedovsky H, Normann S, Schardt M, et al. Endocrine host response during early and late phases of tumor development. Int J Cancer 2000;86:446-57.
45. Holdaway IM, Mason BH, Lethaby AE, et al. Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aus N Z J Surg 1999;69(7):495-500.
46. Rho O, Bol DK, You J, et al. Altered expression of insulin growth factor I and its receptor during multistage carcinogenesis in mouse skin. Mol Carcinog 1996;17(2):62-9.
47. Chemicky CL, Yi L, Tan H, et al. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibit cell growth, suppressed tumorigenesis, alters the metastatic potential and prolongs survival in vivo. Cancer Gene Ther 2000;7(3):384-95.
48. Kobayashi M, Olefsky JM. Effect of streptozotocin-induced diabetes on insulin binding, glucose transport and intracelular glucose metabolism in isolated rat adipocytes. Diabetes 1982;28:87-95.